NASDAQ:SABS SAB Biotherapeutics Inc
entry PTs 3.65 - 4-ish
Target PTs 10 --> 14.50 and higher
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully...
